Gulf Pharmaceutical Sustainability Profile
Gulf Pharmaceutical Industries, commonly known as Julphar, is a leading pharmaceutical company headquartered in the United Arab Emirates (AE). Established in 1980, Julphar has grown to become a prominent player in the Middle East and North Africa (MENA) region, focusing on the development, manufacturing, and distribution of high-quality pharmaceutical products. With a diverse portfolio that includes prescription medications, over-the-counter products, and biotechnology solutions, Julphar is renowned for its commitment to innovation and quality. The company has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities and a robust research and development programme. Julphar's dedication to excellence has positioned it as a trusted name in the pharmaceutical industry, contributing to improved healthcare outcomes across its operational regions.
DitchCarbon Score
How does Gulf Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gulf Pharmaceutical's score of 36 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gulf Pharmaceutical's reported carbon emissions
In 2024, Gulf Pharmaceutical Industries P.S.C. reported total carbon emissions of approximately 48,000,000 kg CO2e, with Scope 1 emissions at about 10,000,000 kg CO2e and Scope 2 emissions at around 35,000,000 kg CO2e. This marks a slight decrease from 2023, when the company also reported total emissions of 48,000,000 kg CO2e in the UAE, with Scope 1 emissions of about 10,000,000 kg CO2e and Scope 2 emissions of approximately 36,000,000 kg CO2e. Gulf Pharmaceutical has set ambitious climate commitments, aiming for net zero emissions by 2050. The company achieved a 3% reduction in Scope 1 emissions and a 2% reduction in Scope 2 emissions from 2022 to 2023, attributed to decreased diesel and electricity consumption. These reductions reflect Gulf Pharmaceutical's ongoing efforts to enhance sustainability and reduce its carbon footprint. The emissions data is not cascaded from any parent organization, indicating that Gulf Pharmaceutical independently reports its emissions and climate initiatives. The company continues to focus on improving its environmental performance in alignment with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 6,300,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 29,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Gulf Pharmaceutical's Industry?
How Carbon Intensive is Gulf Pharmaceutical's Location?
Gulf Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Gulf Pharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
United Pharmaceutical Establishment
Boots UK Limited
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.